Partnerid
Allikad:
Mayo Clinic. ,,Neurofibromatosis type 1: Symptoms and causes". Mayo Clinic, 10.09.2024 (vaadatud 22.04.2026). https://www.mayoclinic.org/diseases-conditions/neurofibromatosis-type-1/symptoms-causes/syc-20350490
National Library of Medicine. ,,Neurofibromatosis type 1". MedlinePlus Genetics; (vaadatud 22.04.2026). https://medlineplus.gov/genetics/condition/neurofibromatosis-type-1/
National Institute of Neurological Disorders and Stroke. ,,Neurofibromatosis". National Institutes of Health; (vaadatud 22.04.2026). https://www.ninds.nih.gov/health-information/disorders/neurofibromatosis
National Health Service. ,,Neurofibromatosis type 1". NHS; (vaadatud 22.04.2026). https://www.nhs.uk/conditions/neurofibromatosis-type-1/
Friedman J. M. ,,Neurofibromatosis 1". Adam MP, Bick S, Mirzaa GM, et al., Seattle (WA): University of Washington (uuendatud 03.04.2025, vaadatud 22.04.2026). https://www.ncbi.nlm.nih.gov/books/NBK1109/
Mayo Clinic. ,,Plexiform neurofibroma - Symptoms and causes". Mayo Clinic (uuendatud 2025, vaadatud 24.04.2026). https://www.mayoclinic.org/diseases-conditions/plexiform-neurofibroma/symptoms-causes/syc-20587495
Fenot M, Stalder JF, Barbarot S. ,,Juvenile xanthogranulomas are highly prevalent but transient in young children with neurofibromatosis type 1". Journal of the American Academy of Dermatology. 01.08.2014. 71(2):389–90. (vaadatud 22.04.2026). https://www.jaad.org/article/S0190-9622(14)01372-3/fulltext
Legius et al. ,,Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation". 23.08.2021. Genetics in Medicine. 23, 8, lk 1506-1513. https://pubmed.ncbi.nlm.nih.gov/34012067/